Pegasys® in Patients With Myeloproliferative Diseases

Status Completed

Clinical Trial Summary

The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to control the disease in patients with ET, PV, AMM/MF, and Ph-negative CML. The safety of this treatment will also be studied.

Clinical Trial Description

IFN-alpha2a has been used for the treatment of a variety of disorders (such as hepatitis C). IFN-alpha2a is a drug that may affect the way infections and malignant diseases develop. Before treatment starts, you will have blood (around 2 teaspoons) and bone marrow samples collected. To collect a bone marrow sample, an area of the hip or chest bone is numbed with anesthetic and a small amount of bone marrow is withdrawn through a large needle. These samples will be used for tests to confirm the diagnosis of the disease. Women who are able to have children must have a negative blood pregnancy test. During treatment, you will receive IFN-alpha2a as an injection under the skin once a week. You (or your caregiver) will be taught how to give the injections, and you will receive treatment on an outpatient basis. Treatment will continue (injections once a week) as long as the disease does not get worse. If the disease gets worse or you experience any intolerable side effects, you will be taken off the study and your doctor will discuss other treatment options with you. During treatment you will have blood (around 1 teaspoon) collected every other week for 2 months, then once every 1 or 2 months for a year, then every 3 months. You will also have bone marrow samples collected every 3 to 6 months during the first year of treatment. After the first year of treatment, bone marrow samples will be collected only when your doctor feels they are needed. The blood and bone marrow samples will be used for tests to check on the response to therapy. This is an investigational study. IFN-alpha2a has been approved by the FDA for the treatment of hepatitis C and is commercially available. However the use of IFN-alpha2a in this study is investigational. The commercial prepartion of IFN-alpha2a(Pegasys) will be used in this study. Up to 280 participants will take part in this study. All will be enrolled at M. D. Anderson. ;

Study Design

Related Conditions & MeSH terms

Myeloproliferative Disorders

Clinical Trial Details

NCT number	NCT00452023
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	April 7, 2005
Completion date	May 26, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Completed	`NCT01684150` - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving	Phase 1
Terminated	`NCT01144780` - Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
Enrolling by invitation	`NCT01728402` - Pathogenesis of Hematologic Malignancies
Completed	`NCT00873574` - JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	N/A
Completed	`NCT00186342` - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies	N/A
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Terminated	`NCT00578539` - T-Reg Cell Kinetics, Stem Cell Transplant, REGALE	N/A
Completed	`NCT01200498` - Study of SB939 in Subjects With Myelofibrosis	Phase 2
Completed	`NCT01135849` - B-Receptor Signaling in Cardiomyopathy	N/A
Completed	`NCT00569842` - Investigation of the Cylex® ImmuKnow® Assay	N/A
Completed	`NCT00283114` - A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	Phase 1
Active, not recruiting	`NCT04631458` - Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
Completed	`NCT01787552` - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF	Phase 1/Phase 2
Terminated	`NCT02766153` - Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
Recruiting	`NCT02320656` - Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015	N/A
Terminated	`NCT00943293` - Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies	Phase 1
Completed	`NCT00038051` - Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies	Phase 1
Completed	`NCT00061581` - Experimental Bone Marrow Transplant Protocol	Phase 2